Riccardo Carloni

Via Albertoni-15
Bologna, 40138, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants.

Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants.

Journal: Cancer medicine

Published: January 14, 2024

Appropriateness of Mini-Invasive Approaches for Nausea and Vomiting Refractory to Medical Therapy in Palliative Care Setting: A Case Report.

Appropriateness of Mini-Invasive Approaches for Nausea and Vomiting Refractory to Medical Therapy in Palliative Care Setting: A Case Report.

Journal: Case reports in oncology

Published: November 25, 2023

Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma.

Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma.

Journal: Journal of hepatocellular carcinoma

Published: February 22, 2023

Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis.

Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis.

Journal: Expert opinion on drug safety

Published: November 25, 2022

Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study.

Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study.

Journal: Medicina (Kaunas, Lithuania)

Published: September 13, 2022

Advances in novel systemic therapies for advanced hepatocellular carcinoma.

Advances in novel systemic therapies for advanced hepatocellular carcinoma.

Journal: Future medicinal chemistry

Published: August 23, 2022

Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine.

Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine.

Journal: Translational oncology

Published: June 29, 2022

Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center.

Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center.

Journal: Current oncology (Toronto, Ont.)

Published: June 09, 2022

Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis.

Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis.

Journal: Journal of personalized medicine

Published: June 08, 2022

Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes.

Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes.

Journal: Cancers

Published: March 30, 2022

Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?

Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?

Journal: Future oncology (London, England)

Published: February 03, 2022

Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials.

Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials.

Journal: Expert opinion on investigational drugs

Published: November 20, 2021

Showing 1-12 of 16

Last Updated: 09/26/2026